TY - JOUR
AU - Solanki, Abhishek
AB - Objectives Most historic trials demonstrating the outcomes bladder-preserving radiotherapy, RT doses of 62–66 Gy have with bladder-preserving radiotherapy (RT) used 64–66 Gy. improved OS compared to lower doses, while dose escalation However, newer data suggest improved outcomes with dose to 67–70 Gy does not improve survival. Our study does not escalation up to 70 Gy. Our objective was to explore the im- support deviating from the standard of 64–66 Gy. pact of dose escalation on overall survival (OS) and to identify . . the optimal radiotherapy (RT) dose in patients with muscle- Keywords Bladder preservation therapy Bladder cancer . . . invasive bladder cancer (MIBC) treated with curative bladder- Radiotherapy Chemoradiotherapy Muscle-invasive preserving RT. Trimodality therapy National Cancer Database Methods We conducted a retrospective cohort study of pa- tients with cT2–4N0–3 M0 transitional cell MIBC who were treated with curative RT (60–70 Gy in 1.8–2.0 Gy/fraction) Introduction using the National Cancer Database. Univariable (UVA) and multivariable (MVA) frailty survival analyses were employed Bladder cancer is one of the most common genitourinary ma- to identify the association of dose escalation to 67–70 Gy, as lignancies, with 79,030 expected new cases of bladder cancer well as different RT dose subgroups within 
TI - Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation
JF - Journal of Radiation Oncology
DO - 10.1007/s13566-017-0319-2
DA - 2017-07-10
UR - https://www.deepdyve.com/lp/springer-journals/maximizing-survival-in-patients-with-muscle-invasive-bladder-cancer-v1goNJ5lIG
SP - 387
EP - 395
VL - 6
IS - 4
DP - DeepDyve
ER -